ipilimumab,nivolumab,cabozantinib
exelixis,bms
['nivo', 'kcsm,(-skcsm)', 'cabozantinib', 'cosmic-313', 'ipilimumab', 'nivolumab', 'renal,(-adrenal)']
#esmo22 highlights: phase 3 study of cabozantinib in combination with nivolumab and ipilimumab in previously untreated advanced #renalcellcarcinoma of imdc intermediate or poor risk (cosmic-313) #kcsm #medtwitter #onctwitter
The European Society for Medical Oncology (ESMO) is the leading organisation for cancer education and information, supporting the oncology community’s work.